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Vaccine-elicited cytotoxic T lymphocytes (CTL) recognizing conserved fragments of a
pathogen’s proteome could greatly impact infectious diseases and cancers. Enabling this
potential are recent advances in mass spectrometry that identify specific target peptides
among the myriad HLA-bound peptides on altered cells. Ultrasensitivity of these physical
detection methods allows for the direct assessment of peptide presentation on small num-
bers of tissue-derived cells. In addition, concurrent advances in immunobiology suggest
ways to induce CTLs with requisite functional avidity and tissue deployment. Elicitation
of high-avidity resident-memory T cells through vaccination may shift the vaccinology
paradigm both for preventive and therapeutic approaches to human disease control.
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VACCINES AND INFECTIOUS CHALLENGES
On a global scale, vaccines have had the greatest impact on human
morbidity and mortality from infectious diseases relative to other
medical interventions (1). Current FDA-approved vaccines are
primarily, if not exclusively, antibody-based in their action, elic-
iting effective neutralizing antibody responses in pathogen-naïve
individuals. Alum-based vaccines are of major clinical utility in
facilitating this humoral response. However, these licensed vac-
cines are protective against pathogens with low antigenic vari-
ability. Thus, little to no antigen variation is detected in diph-
theria, tetanus, H. influenzae B, polio virus, hepatitis A virus,
hepatitis B virus, measles, mumps, or rubella viruses. Influenza A
virus sequence variability, in contrast, being annual in timescale,
requires educated guessing as to appropriate subtype for vac-
cine formulation to prophylax against future outbreaks. This
forecasting approach is only partially successful.
Conventional vaccines against viruses with high mutational
rates like hepatitis C virus (HCV) and human immunodeficiency
virus-1 (HIV-1), which evolve changes daily under immune selec-
tion pressure, or even influenza viruses, which evolve mutations
more slowly, will fall short due to intrinsic antibody-evading
mechanisms (2). These viruses can avoid attack by immune
memory cells through mutation, leaving “yesterday’s” adaptive
immune system unable to cope with evolving changes in the
viral proteins. Immune escape follows. While it has long been
recognized that conserved segments of viral pathogens that can-
not mutate due to detrimental effects on viral fitness would be
ideal targets against which to engender cross-protective immu-
nity via T cells, the way to implement such an approach has been
unclear.
Abbreviations: CTL, cytotoxic T lymphocytes; LN, lymph node; MS, mass spec-
trometry; pMHCI, peptide bound to major histocompatibility complex class I
molecule; TCR, T cell receptor.
CTL TARGETING
It is our view that a key path forward involves development of CD8
cytotoxic T lymphocytes (CTL) vaccines. As shown in Figure 1,
there are four components of an effective CD8-based T cell vaccine
pipeline: (1) facile bioinformatic prediction of conserved segments
that include potential T cell epitopes from variable viral strains;
(2) physical detection methodologies, most notably mass spec-
trometry (MS), to determine which of the predicted epitopes are
actually arrayed on infected and antigen presenting cells (APCs)
for T cell recognition by T cell receptors (TCRs); (3) nanovaccine
technology to deliver conserved T cell epitope payloads including
adjuvants to APCs for stimulating epitope display in appropriate
lymphoid tissue and with optimal display density and time course;
and (4) insightful memory T cell biology arising from transcrip-
tomics, proteomics, and other molecular analyses of CD8 subsets
defining their development into effector and memory components
and the rules guiding their physical deployment into epithelial
and lymphoid compartments. Collectively, these technologies and
knowledge will create vaccines that elicit potent CD8 memory T
cells with effector function that reside at sites of potential viral
attack. Such resident-memory T cells (TRM) are positioned for
immediate action and are in turn aided by subsequent recruitment
of T effector (TEM) and T central memory cells (TCM) from blood
and secondary lymphoid tissues. In this way, a prompt immune
response is engendered that minimizes viral replication with its
pathological consequences. Until very recently, the existence of
this important TRM subset with its unique biology was unknown.
TRM exhibit a CD103 cell adhesion profile, TGFβ responsiveness
and in contrast to circulating CD8 T memory cells, do not need
IL-7 and IL-15 for tissue-resident homeostasis (3, 4).
This perspective focuses primarily on physical detection since
advances in this area augment CD8 vaccine development efforts
in ways that have not been reviewed and are paradigm-shifting.
Our view is that the MS approach herein has application to
a multiplicity of infectious diseases as well as cancers caused
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FIGURE 1 | Essential components of efficacious CD8 vaccine
development.
by viruses. Upwards of 20% of tumors worldwide are caused
by viruses, with high-risk human papillomaviruses (HPV) alone
responsible for >5% of all cancers (5). Computational methods
are already available for prediction of peptide binding to multiple
HLA alleles, population coverage based on HLA frequencies can
be estimated, and there are bioinformatic tools and databases to
focus on peptide epitopes conserved among diverse strains of a
given virus [(6, 7) and references therein]. Vaccine technology
using synthetic materials to target organs, tissues, or cells and
deliver concurrently epitopes and immunomodulatory payloads
also exist (8).
PHYSICAL DETECTION
The interaction between a TCR on a CTL and a peptide-bound
HLA ligand on an APC [referred to more generally as a peptide-
major histocompatibility class I complex (pMHCI) in humans
and other mammals] triggers a spectrum of T cell responses in
structurally defined terms (9). The molecular definition of the
relevant pMHC being recognized is absolutely essential in under-
standing adaptive immunity. In clinical settings, identification of
surface pMHC is generally undetermined or inferred. Although
clever use of transgenic clones and engineered infections (10)
can circumvent identification of unknown surface pMHC and
these methods have led to deep mechanistic insights to rationally
develop T cell vaccines, one cannot avoid molecular identifica-
tion. A primary tool for peptide identification has been to iso-
late antigen-experienced T cells from some tissue compartment
and demonstrate that these cells functionally “recognize” specific
pMHCI. Unfortunately, there are many technical issues imple-
menting this reverse immunology approach. For example, ex vivo
T cell lines that functionally respond to APCs loaded with peptides
at high levels may be unable to recognize the low levels of antigen
display characteristic of infection or viral transformation. As APC
loading levels are defined only by the solution concentration of the
peptide with neither the pMHCI density on the loaded APC or on
the infected/transformed cell being known, the disparity in T cell
avidity between recognizing loaded APCs and recognizing infected
cells remains unknown. Beyond technical issues is a fundamental
problem: in principle, reverse immunology identifies only anti-
genic peptides and not those non-antigenic foreign peptides that
are displayed as surface pMHCI (vide infra).
As MS is the premiere analytical method for the sensitive identi-
fication of peptides in complex mixtures, the very limited literature
reports of identifying pathogen-derived MHCI/peptide by MS
proteomics is notable, but not surprising. The analytical challenge
for MS is twofold. First, MHCI peptides are derivatives of total
protein metabolism and this complex set is bound to a small set of
different MHC proteins on the cell surface. T cells can recognize
a few specific pMHCI copies per cell among 100,000 irrelevant
other peptides on the same cell (11). Fundamental and practical
constraints limit the number of infected or excised cells available
for analysis, requiring both high dynamic range and high absolute
sensitivity for immunologically useful MS analysis. Second, MHCI
peptides are similar in amino acid residue number and hydropho-
bicity due to MHC-binding requirements resulting in crowding
along both the m/z (mass/charge) axis and the chromatographic
elution time axis that characterize peptides and their fragments.
For samples like this, standard proteomics can identify thousands
of the major components without identifying the immunologically
important but quantitatively minor peptides within the pool.
Our laboratory has applied the theory of probabilistic measures
for stochastic processes to recognize an ion’s fragmentation pat-
tern when it is set among a complex set of other ion fragments.
In general, ion arrival rates in different m/z channels of the mass
spectrometer is a Poisson process and a Poisson measure is used to
assign a magnitude of a target molecule’s fragmentation spectrum
when it is buried among ion fragments from unrelated molecules.
In one format, denoted MS3 Poisson detection, the measure has
been applied to detecting MHCI peptides without LC separations.
Using static nanospray, MS3 spectra are generated directly from
the complex mixture by first isolating and fragmenting a precur-
sor m/z and then isolating and fragmenting a selected fragment
of the precursor. The MS3 spectrum is the mass spectrum of the
fragment of a fragment of a molecular ion. Prior to analyzing the
mixture, the pure molecule (e.g., synthetic peptide) will have been
studied to determine the optimal MS3 spectra for detection and
these spectra acquired for later use. MS3 spectra of the mixture
are then acquired with the same m/z selection steps and the prob-
abilistic measure determines if the target molecule’s MS3 spectra
are present against the background of other molecules that had
the same molecular m/z and generated the same fragment m/z.
The two m/z selection steps act somewhat like chromatography in
that they simplify the overall ion population while increasing the
fraction of the ions that are derived from the target molecule. Two
important features have been shown. First, the dynamic range of
detection,defined as the target’s fraction of the total ion flux,can be
directly estimated and is on the order of 105. Second, the sensitiv-
ity of MS3 Poisson detection compares well with the most sensitive
T cell clone that we have generated. The theory of the method and
its use in identifying HPV antigens has been published (12–14).
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In a second format, the Poisson measure is used to recognize a
target ion’s MS2 fragment spectrum against a complex background
of other ion fragments in a data-independent acquisition (DIA)
format. Here different m/z ranges of precursor ions are selected
and dissociated with the set of m/z ranges selected covering all
precursor ions of interest. When selecting an m/z interval for frag-
mentation, ions outside the interval are lost. Better sensitivity is
associated with selecting fewer, and therefore, wider, m/z intervals.
However, wider m/z intervals increase the fragment background
relative to the target’s fragments and here the Poisson measure
is applied. The Poisson measure of any target is then calculated
for each scan and plotted as a chromatogram. In a DIA format,
prior knowledge of the target’s MS2 spectrum is not required for
data acquisition outside of the target ion’s m/z being contained
in at least one of the selected m/z intervals. Knowledge of the
MS2 spectrum is required only later when the amassed data are
being mined for a specific molecular ion. Using organic mono-
lithic columns with flow rates of 10 nl/min and collecting a series of
overlapped m/z intervals, highly sensitive Poisson detection chro-
matograms for targets defined post-acquisition can be generated
(Poisson segmented LC-MSE). Rapid electronic data capture, high
resolution mass spectrometers and information-rich precursor,
and ion fragment beams allow deep targeted interrogation and
re-interrogation of precious samples after the sample is acquired
and data archived. Poisson MS3 and segmented LC-MSE have very
different strengths and are highly orthogonal in the features that
they employ for detection. Their combination we have found is
considered to be most effective.
DIRECT PRESENTATION VERSUS CROSS-PRESENTATION
CD8 TCM and TEM are thought to circulate through blood, inter-
converting while passing through lymphoid and non-lymphoid
tissues (15, 16). Emerging evidence indicates that TRM reside long-
term in the brain and mucosal tissues (such as the lungs, gut, and
skin) and show only limited levels of egress and recirculation (17).
These cells have a characteristic CD103hiCD69hiCD27low pheno-
type and may express high levels of granzyme B. The signaling
pathways and transcriptome components regulating formation of
these heterogeneous populations are coming to light (18). TRM
populations have been identified as embedded within barrier
epithelial surfaces both in humans and rodents. CD8 TRM cells
rapidly acquire cytotoxic function after encountering pMHCI.
For viral infection, the outcome at barrier surfaces is a compe-
tition between the production of new viral particles by infected
host cells vs. immune protection afforded by CTL recognition and
destruction of infected or transformed cells. The finite number
of TRM cells at mucosal surfaces with limited scanning mobility
places a great premium on matching TRM specificities to MHCI
display of pathogens on infected cells. TRM cells link antigen speci-
ficity with tissue localization, in part through expressing integrins
imprinted by draining lymph nodes (LN). Enriching the TRM pop-
ulation specific for pathogens that are likely to be encountered at
a given site based on previous encounters makes immunological
sense. However, T cell homing only connects the antigen display
of professional APCs in draining LN with the antigen source in the
periphery; it does not identify or instruct which pMHC should
be recognized. The display of pathogen determinants in LN is
dependent on antigen trafficking and cross-presentation, while
the display at barrier surfaces reflects the direct presentation of
infection. It is not sufficient that some of the determinants on
professional APCs are displayed in common with infected tissue
parenchyma. Stimulation of CTL by APC display that is function-
ally irrelevant for destruction of infected epithelium may even
yield positive functional readouts in ELIspot or other assays, but
this response is no biomarker of protection.
The objective for CTL vaccination is to establish an opti-
mal, functionally avid TRM population focusing on the MHCI
presentation of pathogen determinants displayed at the epithe-
lial barrier of an infected organ. Cytotoxic response should tar-
get determinants that are displayed by infected host cells at
early time points in order to eliminate these cells prior to sig-
nificant viral replication. The cellular scale and sensitivity of
the aforementioned MS Poisson detection methods permit such
identification.
Of note, in cases where HPV-16 infection has induced epithe-
lial transformation and cervical cancer in HLA-A*0201 hosts, only
a single epitope from the E7 oncogene product, E711–19, is natu-
rally processed and presented by this allele on those tumor cells.
Pointedly, although E711–20 is capable of binding equivalently to
this same HLA allele, the 10-mer peptide, unlike the 9-mer, is not
displayed on the primary epithelial cells. In contrast, when a large
fragment of E7 as a synthetic peptide is exogenously added to
HLA-A*0201 professional APCs, the E711–20 is displayed to a very
large extent (14). Since T cells are not strongly crossreactive and
are particularly specified to a single peptide length (19, 20), this
discordance misguides the immune response. It also explains, in
significant part, why the 10-mer vaccine was without clinical effect
in a therapeutic HPV-16 cancer trial (21).
CD8 T CELLS: FUNCTIONAL AVIDITY, ELICITATION, AND
DEPLOYMENT
Functional avidity refers to the sensitivity of a particular T cell to
be triggered by pMHC on an APC. High-avidity T cells are capa-
ble of recognizing a very small number of pMHC/target cell (i.e.,
single digit), whereas low-avidity T cells may require hundreds
(22–24). Avidity is dependent on the TCR–pMHC interaction,
CD8 co-receptor expression, intracellular signaling molecules, and
other factors (25). With respect to the TCR, the Vβ and Vα gene
repertoire and the nature of the antigen itself both contribute.
Unfeatured pMHCI surfaces, like influenza A M158–66 bound to
HLA-A*0201, strongly elicit T cells which, although plentiful,
comprise a low-avidity immunodominant response (26, 27). As
such, display requirements on infected epithelium for activation
of those CTL may be at too high a copy number to be achieved
during natural infection. Consequently, this CTL response would
be non-protective. By using next generation sequencing technolo-
gies to identify T cell antigen-specific repertoires and rapid αβ
TCR cloning and expression systems (28), their functional TCR-
pMHC binding characteristics can be cataloged. In conjunction
with quantitation of a given viral pMHC copy number on epithe-
lium or other cells during early infection, the best epitopes can
be selected for CTL elicitation through vaccination. In turn, slow
release of these epitopes from nanovaccines or other biomaterials
formulation (8) in conjunction with routes of administration and
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chemokines to foster dissemination in relevant tissues (29) can
afford optimal protection.
Imagine a time in which CTL-eliciting vaccines are predicated
on knowledge of the actual HLA-linked viral peptidome with
epitope formulations reflecting peptides conserved in sequence
among viral strains and displayed at the earliest time points of
infection in numbers sufficient to elicit responding TCRs from the
human repertoire. If this could be applied to influenza A, for exam-
ple, a single vaccine incorporating a few such epitopes would be
sufficient, in principle, to afford protection against both seasonal
and pandemic variants and bird or swine flu (6). Assuming that
we can amalgamate advances in ion physics, structural biology,
immunology, computer science, and virology, there is no reason
to expect such advances will not be achievable.
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